Giant Cell Tumor of Bone

Giant Cell Tumor of Bone is a type of bone growth. It usually happens in younger adults, often near the ends of long bones like the thigh or shin. While most are harmless, sometimes they can grow larger or cause problems.

Condition

What people with Giant Cell Tumor of Bone report

Every report comes from a Lived member, sent anonymously.

Have you had Curettage for Giant Cell Tumor of Bone?

NameHow it went

About Giant Cell Tumor of Bone

What It Is

Giant cell tumor of bone is an uncommon tumor that starts inside a bone, usually at the end of a long bone where it forms part of a joint. The knee is the most common site (the lower end of the thighbone or the upper end of the shinbone), followed by places such as the wrist, hip, shoulder and the sacrum at the base of the spine. It mostly affects adults between about 20 and 45, after the skeleton has finished growing, and is slightly more common in women. It is also called osteoclastoma. Most giant cell tumors are benign, meaning they are not cancer. They still need treatment because they grow and dissolve the bone around them, which can weaken the bone, damage the nearby joint surface and lead to a fracture. They also have a strong tendency to come back after surgery. In a small minority of people the tumor spreads to the lungs while still looking benign under the microscope, and very rarely it is or becomes a true cancer (malignant giant cell tumor). The name comes from the large cells with many nuclei seen under the microscope. These giant cells resemble osteoclasts, the cells that normally break down old bone, and they do the bone destruction. The actual tumor cells are smaller cells around them, which send out signals that recruit and switch on the giant cells.

Causes & Risk Factors

The cause is not known. In nearly all cases the tumor cells carry a change in a gene called H3F3A, but this change arises in the tumor itself. It is not inherited from a parent, and giant cell tumor of bone is not considered a family condition. There is no established link to injury, diet or lifestyle. The tumor cells make large amounts of a signaling protein called RANKL, which drives the giant cells to dissolve bone. This explains how the tumor causes damage, and it is the target of the medicine denosumab, but it does not explain why the tumor starts in the first place. The clearest pattern is age: the tumor is uncommon before the growth plates close and uncommon after 50. It is reported more often in parts of Asia, including China and southern India. Rarely, it occurs alongside Paget disease of bone, a condition of disordered bone renewal that mainly affects older adults.

How It's Diagnosed

Assessment usually starts with an examination and an X-ray. On X-ray the tumor typically appears as a dark, "eaten away" area at the end of a bone that reaches toward the joint, sometimes with the bone's outer shell thinned or bulging. This look is suggestive but not specific, because several other bone conditions resemble it. An MRI shows how far the tumor extends inside the bone and whether it has broken through into nearby soft tissue, and a CT scan shows how much solid bone remains around it. Doctors use these images to grade how aggressive the tumor looks, from fully contained within the bone to breaking through the bone's outer wall, and that grade guides which operation makes sense. A chest CT or chest X-ray is done at diagnosis because the tumor occasionally has already spread to the lungs. A biopsy, a sample of tumor tissue taken with a needle or through a small incision, confirms the diagnosis. Giant cells also appear in other bone lesions, including some bone cancers, so the sample should be read by a pathologist experienced with bone tumors. A stain that detects the altered protein made by the H3F3A gene change helps separate giant cell tumor from look-alikes. The evaluation also considers a brown tumor, a bone lesion caused by an overactive parathyroid gland, which can look similar but is treated differently.

Treatment Options

Treatment is needed because the tumor keeps destroying bone if left alone. Surgery is the main treatment and the one most likely to remove the tumor for good. It is best planned by an orthopedic oncology team, meaning surgeons who specialize in bone tumors. The most common operation is curettage. The surgeon opens a window in the bone, scrapes out the tumor and often uses a high-speed burr to clear the cavity walls. Extra measures such as freezing with liquid nitrogen or rinsing with chemicals (phenol or hydrogen peroxide) may be used to kill remaining tumor cells, and the cavity is usually filled with bone cement, bone graft or both. Curettage keeps the person's own joint, which usually means better long-term function, but the tumor comes back in a meaningful share of people (in many reports roughly one in five to one in three). Cement gives immediate support and makes a recurrence easier to spot on X-rays. Cement placed right under the joint surface may contribute to later arthritis, so surgeons sometimes place bone graft beneath the cartilage first. When the tumor has destroyed much of the bone or joint, the surgeon may instead remove the whole affected section of bone (resection) and rebuild it with a joint replacement, donor bone or both. This makes recurrence much less likely but is a larger operation, with more loss of function. Denosumab (Xgeva) is an injected antibody that blocks RANKL, the signal the tumor uses to switch on the bone-dissolving giant cells. It is FDA-approved for adults and for adolescents whose skeletons have finished growing when the tumor cannot be removed or removing it would cause severe disability, as is often the case in the sacrum or spine. It usually halts bone destruction and can harden and shrink the tumor, but it does not eliminate the tumor cells, so the tumor tends to regrow when treatment stops and many people stay on it long term. Giving it for a few months before routine curettage of an arm or leg tumor has been linked to more recurrences, so it is generally not used that way when the joint can be saved. Treatment involves calcium and vitamin D, a dental check before starting because of a risk of jaw bone damage that grows with longer treatment, and pregnancy planning: denosumab can harm a developing baby, which matters because this tumor mostly affects people of childbearing age. Other options are used selectively. Embolization blocks the arteries feeding the tumor, usually before surgery to reduce bleeding, and sometimes on its own when surgery is not possible. Radiation therapy is reserved mainly for spinal tumors that cannot be controlled another way, because older radiation techniques were linked to later cancerous change. If the tumor spreads to the lungs, small spots may simply be watched, while others are removed surgically or treated with denosumab.

What to Expect

With treatment, most people with a benign giant cell tumor keep their limb and many return to their usual activities. The outcome depends on the tumor's size and location, how much of the joint was involved and which operation was needed. After curettage with cement, many people can put weight on the limb fairly early, while removing and rebuilding a joint means a longer recovery and rehabilitation. Some people develop arthritis in the nearby joint in later years. The main ongoing concern is the tumor coming back, which can happen months or years after surgery. It often shows up as new pain or as a change on a follow-up scan, and most recurrences after curettage can be treated with another joint-sparing operation. Follow-up therefore continues for several years, with imaging of the treated bone and of the chest. There is no single agreed schedule; checks are usually more frequent in the first couple of years and then spaced out. Lung spread is uncommon. When it happens it often grows slowly, and some people live with stable spots for years, but in others it progresses and needs active treatment. People on long-term denosumab have regular injections, blood calcium checks and dental care. Stopping the drug is planned with the team, because the tumor can reactivate and blood calcium can rise in the year after the last dose.

When to Seek Help

See a doctor if pain near a joint gradually worsens over weeks, especially with activity, or comes with swelling, a lump or stiffness that does not settle. Persistent pain like this in a young or middle-aged adult is worth an X-ray. If you have been diagnosed or treated, contact your care team promptly about new pain, swelling or loss of movement at the treated site, a cough or breathlessness that does not go away, or, with a tumor in the spine or sacrum, numbness or weakness in the legs that develops gradually. Sudden severe pain at the tumor site, especially if you cannot put weight on the limb or use it, may mean the weakened bone has broken and needs same-day medical assessment. With a tumor in the spine or sacrum, sudden or quickly worsening leg weakness, new numbness in the groin or buttocks, or new loss of bladder or bowel control needs emergency care right away. These signs can mean the tumor is pressing on the spinal cord or nerves, and the chance of recovering function is best when that pressure is relieved quickly.

Questions to Ask Your Doctor

  1. 1.What do my scans show about how far the tumor extends, and has the biopsy been reviewed by a pathologist experienced with bone tumors?
  2. 2.For a tumor in this location, how do curettage and removing the bone section compare for the chance of recurrence and how my joint will work afterward?
  3. 3.Would denosumab or another treatment help in my case, and how would it affect pregnancy plans or dental care?
  4. 4.What will my follow-up look like, including chest imaging, and for how many years?
  5. 5.What activity limits and rehabilitation should I expect after surgery?

Last reviewed • Oct 2026

Educational content, not medical advice.